[ADARx Pharmaceuticals, Inc.] ADARx Pharmaceuticals, Inc. announced that it has received Fast Track designation from the US FDA for onvuzosiran, an investigational small interfering RNA therapeutic candidate, for prophylaxis to prevent attacks of hereditary angioedema (HAE). The underlying cause of HAE is an abnormality in the kallikrein-kinin cascade resulting in increased bradykinin.

[Nature Communications] Focusing on the well-established angiocrine Wnt signaling-regulated liver metabolic zonation paradigm, researchers identified blood flow-induced hemodynamic stress as a biophysical sensor that governs the angiocrine expression profile of liver sinusoidal endothelial cells.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers identified the RNA demethylase ALKBH3 as an epitranscriptional driver of diabetic microvasculopathy. Upregulated ALKBH3 in diabetic vascular endothelial cells promoted a pathological shift to an unstable, pro-angiogenic phenotype, disrupting blood-retinal barrier and forming immature neovessels, which impaired vision.

[Science Advances] Scientists described a charge-altering releasable transporter that delivers RNA selectively to the corneal endothelium, a non-regenerative cell layer whose dysfunction underlies several blinding conditions.

[Circulation Research] Scientists identified formyl peptide receptor 1 (FPR1) as a pivotal regulator in peripheral artery occlusive disease (PAOD). Fpr1 deficiency led to exaggerated inflammation and impaired angiogenesis, whereas FPR1 activation by a biased agonist, Cmpd17b, attenuated inflammation and improved perfusion recovery through a neutrophil‑dependent mechanism.

[Acta Pharmacologica Sinica] Emerging evidence suggests that dysregulated neddylation contributes to several metabolic abnormalities implicated in endothelial dysfunction, including insulin resistance, obesity-associated metabolic dysfunction, oxidative stress, and mitochondrial dysfunction.

[Apoptosis] The authors summarize recent advances in biomaterial-supported organoid systems for dissecting endothelial cell heterogeneity and its contribution to aberrant angiogenesis in endometriosis.

[Molecular Aspects of Medicine] Scientists advance the hypothesis that gestational diabetes mellitus and cancer share conserved endothelial adaptive response mechanisms, particularly within the placental and tumour-associated vasculature, without implying malignant transformation or direct oncogenic causation.

[Bone Research] The authors summarize vascularization strategies for bone organoids, including in vitro approaches, in vivo integration, and bioengineering technologies.

[Science Advances] Investigators demonstrated that ETS variant transcription factor 2 (ETV2) drives the rapid forward programming of hPSCs into endothelial cells by direct remodeling of endothelial-specific enhancers.

[European Heart Journal] Scientists used patient-specific iPSC-derived endothelial cells, engineered cardiac organoids, and the LMNAH222P/H222P mouse model to investigate RUNX1-mediated endothelial-to-mesenchymal transition.

[Nature Medicine] Scientists conducted the HEAL-CHF trial, in which patients with advanced heart failure with reduced ejection fraction were randomized to receive intramyocardial injections of allogeneic hiPSC-derived cardiomyocytes or were uninjected.